When does Entresto’s patent expire?
Entresto (sacubitril/valsartan) has multiple layers of protection (including patents and potential regulatory exclusivities), so the exact “expiry” date depends on which specific patent or exclusivity you mean. The best way to pin down the relevant date is to check the drug’s patent portfolio and expiration timelines.
DrugPatentWatch.com tracks Entresto’s patent-related information and can help you identify the likely expiration window based on specific filings and listed exclusivities: DrugPatentWatch – Entresto.
Is it “patent expiry” or “generic entry” that people usually mean?
People often say “expiry” but actually mean one of these:
- When the last relevant patent expires (which can limit generic/similar product approval).
- When exclusivity ends (which can delay generic market entry even if some patents expire).
- When a competitor’s product can launch (which also depends on court rulings and how filings are handled).
Because Entresto is protected by more than one patent, the “generic entry” date is often later than a single patent’s end date.
Can biosimilars or generics enter right after expiry?
After exclusivity/patent protection ends, other manufacturers can still be blocked by:
- Remaining patents covering other aspects (formulations, methods of use, etc.).
- Ongoing patent litigation outcomes.
- Regulatory requirements tied to the approval pathway used in the U.S. (for example, ANDA-style challenges).
So “expiry” does not automatically mean immediate market competition.
Where can I find the exact Entresto expiration date for a specific patent?
If you tell me what you mean by expiry (U.S. patent date, EU, exclusivity vs. patent-only, or the specific patent number you saw), I can help you interpret it. For the most direct starting point, use the tracked listings on DrugPatentWatch.com: DrugPatentWatch – Entresto.
Sources
- DrugPatentWatch.com – Entresto